Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Visudyne (verteporfin) - Important Safety Information from Novartis as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
08/05/2007
Problem Or Issue:
Please find attached Safety Communication from Novartis in respect of a clinical study with Visudyne (verteporfin) in occult choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD).
« Back
Date Printed: 20/09/2024